Canaccord Lowers Niagen Bioscience, Inc. (NAGE) PT on Updated Forecasts Following Q4 Results

We recently compiled a list of the 12 Penny Stocks with Insider Buying in 2026. Niagen Bioscience, Inc. is one of the best stocks with insider buying. 

TheFly reported on March 5 that Canaccord Genuity revised its price target for NAGE to $13, down from $14, while maintaining a Buy rating. The adjustment follows updated modeling after the company’s Q4 results, which showed continued robust demand for its main product lines. The firm also highlighted potential growth opportunities in NAGE’s injectable segment, noting that this area could contribute additional upside for the business.

Separately, on March 19, Niagen Bioscience, Inc. (NASDAQ:NAGE) announced that its board of directors approved an increase to the company’s existing share repurchase program, doubling the total authorization from $10 million to $20 million of outstanding common stock.

As of March 17, the company had already repurchased roughly $2.6 million of its shares under this program. The expansion of the buyback authorization reflects the company’s continued focus on returning capital to shareholders while providing additional flexibility to repurchase stock in the open market. The move positions NAGE to manage its capital structure proactively while supporting shareholder value.

Niagen Bioscience, Inc. (NASDAQ:NAGE) is a Los Angeles–based bioscience company pioneering NAD⁺ research and healthy‑aging solutions, best known for its patented nicotinamide riboside ingredient powering Tru Niagen supplements and other NAD⁺‑boosting products backed by scientific research.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.